CJJ300 is a transforming growth factor-β ( TGF-β ) inhibitor with an IC 50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex In Vitro CJJ300 disturbs protein-protein interactions and prevents TGF-β receptor dimerization (IC 50 = 23.6 ± 5.8 µM). CJJ300 (0-80 µM, 2 h) inhibits the phosphorylation of intracellular mediators in the downstream TGF-β signaling pathways, and suppresses the expression of markers of EMT (epithelial-mesenchymal transition) without cytotoxicity. CJJ300 suppresses TGF-β induced cell migration. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Human A549 lung epithelial cells Concentration: 20, 40, and 80 µM Incubation Time: 2 h Result: Significantly attenuated the increasement of P-Smad2/Smad3, P-Erk1/2 and P-Akt induced by TGF-β. Down regulated the expression of EMT-associated proteins, including fibronectin, α-SMA and MMP-2 in a dose-dependent manner. Form:Solid IC50& Target:IC 50 : 5.3 µM (TGF-β1-induced luciferase)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
CJJ300
CAS number：1807631-83-9 molecular formula：C30H33N3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1807631-83-9 | molecular formula | C30H33N3 |
| molecular weight | 435.60 g/mol | Exact mass | ≥95% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
